معرفی
Magdalena Plebanski is an internationally-recognized Adjunct Professor in Immunology at Monash University's Alfred Hospital. Her research focuses on developing affordable vaccines and treatments for malaria, cancer, and allergic diseases using innovative nanoparticle technologies. She has pioneered synthetic non-inflammatory nanoparticles for vaccine applications and contributed to understanding cancer immunology through clinical trials in leukemia and ovarian cancer.
Her career includes significant contributions from Oxford University and collaborations across multiple institutions. She leads >50 patents across 10 families, founding biotech companies. With over 150 peer-reviewed publications in top journals like Nature and Science, her work aligns with UN SDGs for health and innovation.
Plebanski has secured grants from NHMRC and international bodies, leading projects like the TBV malaria vaccine and ovarian cancer immunity studies. Her research emphasizes translational medicine, diagnostics, and immunotherapy advancements.
- Key Projects: Multiplex Ovarian Cancer Diagnostic, TBV Malaria Vaccine, Immunity-Ovarian Cancer Link
- Awards: Not explicitly listed but implied by her international recognition and patent success
- Labs/Teams: Collaborates with multidisciplinary teams in nanotechnology, immunology, and oncology
